Opthea Ltd
ASX:OPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fastighetsbolaget Emilshus AB
STO:EMIL PREF
|
SE |
Opthea Ltd
Other Items
Opthea Ltd
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Opthea Ltd
ASX:OPT
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Other Items
-$58k
|
CAGR 3-Years
23%
|
CAGR 5-Years
44%
|
CAGR 10-Years
4%
|
|
|
CSL Ltd
ASX:CSL
|
Other Items
-$15m
|
CAGR 3-Years
89%
|
CAGR 5-Years
5%
|
CAGR 10-Years
25%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Other Items
-AU$18.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Other Items
-AU$229.9m
|
CAGR 3-Years
-384%
|
CAGR 5-Years
-213%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Opthea Ltd
Glance View
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing and commercializing therapies primarily for eye diseases. The firm's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The firm's technology platform focuses on vascular endothelial growth factors, such as VEGF C, VEGF D and VEGF Receptor 3 for the treatment of diseases associated with blood and lymphatic vessel growth (angiogenesis and lymphangiogenesis), as well as vascular leakage. The company has also conducted various activities to support its clinical development programs in wet AMD and DME, including clinical data analysis and manufacturing of OPT-302 for use in Phase III clinical trials.
